Vaxxinity
-
Vaxxinity Receives FDA Fast Track Designation for UB-311 for Treatment of Alzheimer’s Disease
Vaxxinity Receives FDA Fast Track Designation for UB-311 for Treatment of Alzheimer’s DiseaseVaxxinity Receives FDA Fast Track Designation for UB-311 for Treatment of Alzheimer’s Diseasemore -
Vaxxinity CEO Mei Mei Hu on vaccine research and democratising health
Vaxxinity CEO Mei Mei Hu on vaccine research and democratising healthVaxxinity CEO Mei Mei Hu on vaccine research and democratising healthmore -
COVAXX Initiates Phase 1 Clinical Trial of COVID-19 Vaccine UB-612 in Taiwan
COVAXX Initiates Phase 1 Clinical Trial of COVID-19 Vaccine UB-612 in TaiwanCOVAXX Initiates Phase 1 Clinical Trial of COVID-19 Vaccine UB-612 in Taiwanmore -
Beyond the Spike: The COVAXX Approach to a COVID-19 Vaccine
Beyond the Spike: The COVAXX Approach to a COVID-19 VaccineBeyond the Spike: The COVAXX Approach to a COVID-19 Vaccinemore -
The Most Powerful Vaccine You’ve Never Heard Of | Tony Robbins + Peter Diamandis Webinar
The Most Powerful Vaccine You’ve Never Heard Of | Tony Robbins + Peter Diamandis WebinarThe Most Powerful Vaccine You’ve Never Heard Of | Tony Robbins + Peter Diamandis Webinarmore
